WASHINGTON: US drugmaker Eli Lilly on Wednesday (May 3) announced its experimental Alzheimer’s drug significantly slowed cognitive and functional decline, results hailed as “remarkable” by experts. In a placebo controlled trial of nearly 1,200 people with early forms of the disease, donanemab slowed the progression of symptoms by 35 per…Read More
Remarkable Alzheimer drug reduces cognitive decline results show
